BioMarin Pharmaceutical
 |
|
| Public company | |
| Traded as |
NASDAQ: BMRN NASDAQ-100 Component |
| Industry | Biotechnology |
| Founded | 1997 |
| Founders | Christopher Starr Glen W. Denison Jr. |
| Headquarters | San Rafael, CA, United States |
|
Key people
|
Jean-Jacques Bienaime, Chief Executive Officer Henry J. Fuchs, Chief Medical Officer Dan Spiegelman, Chief Financial Officer |
| Products | Kuvan, Naglazyme, Aldurazyme, Firdapse, Vimizim |
| Revenue |  US$ 889 million (2015) |
 US$ -171 million (2015) |
|
| Total assets | US$ 2.49 billion (2014) |
| Total equity | US$ 1.52 billion (2014) |
|
Number of employees
|
2200 (2016) |
| Website | www.biomarin.com |
|
Footnotes / references |
|
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
In 2002, BioMarin acquired Glyko Biomedical.
In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert-Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.
In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.
...
Wikipedia